Insider Transactions in Q1 2025 at Leap Therapeutics, Inc. (LPTX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2025
|
Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+23.44%
|
-
|
|
Mar 28
2025
|
Cynthia Sirard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+45.0%
|
-
|
|
Mar 28
2025
|
Christopher Mirabelli Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
6,672
-24.19%
|
$0
$0.32 P/Share
|
|
Mar 28
2025
|
Christopher Mirabelli Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+44.92%
|
-
|
|
Mar 28
2025
|
John Mark O'Mahony Chief Manufacturing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+45.0%
|
-
|
|
Mar 28
2025
|
Augustine Lawlor Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,797
-28.26%
|
$0
$0.32 P/Share
|
|
Mar 28
2025
|
Augustine Lawlor Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+44.92%
|
-
|
|
Mar 28
2025
|
Jason Baum Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,604
-29.35%
|
$0
$0.32 P/Share
|
|
Mar 28
2025
|
Jason Baum Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+50.0%
|
-
|
|
Mar 28
2025
|
Christine Granfield VP, Head of Reg Affairs/Qual |
SELL
Payment of exercise price or tax liability
|
Direct |
6,604
-29.35%
|
$0
$0.32 P/Share
|
|
Mar 28
2025
|
Christine Granfield VP, Head of Reg Affairs/Qual |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+50.0%
|
-
|